CR20190393A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents
Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)Info
- Publication number
- CR20190393A CR20190393A CR20190393A CR20190393A CR20190393A CR 20190393 A CR20190393 A CR 20190393A CR 20190393 A CR20190393 A CR 20190393A CR 20190393 A CR20190393 A CR 20190393A CR 20190393 A CR20190393 A CR 20190393A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ahr
- aryl hydrocarbon
- hydrocarbon receptor
- compounds
- modulator compounds
- Prior art date
Links
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 title abstract 9
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000005557 antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000157 | 2017-02-01 | ||
| PCT/EP2018/052538 WO2018141855A1 (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190393A true CR20190393A (es) | 2019-10-21 |
Family
ID=57960222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190393A CR20190393A (es) | 2017-02-01 | 2018-02-01 | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11376241B2 (es) |
| EP (1) | EP3577115B1 (es) |
| JP (1) | JP2020505467A (es) |
| KR (1) | KR20190113902A (es) |
| CN (1) | CN110234650A (es) |
| AR (1) | AR110790A1 (es) |
| AU (1) | AU2018216955B2 (es) |
| BR (1) | BR112019015704A2 (es) |
| CA (1) | CA3051034A1 (es) |
| CL (1) | CL2019002112A1 (es) |
| CO (1) | CO2019007882A2 (es) |
| CR (1) | CR20190393A (es) |
| CU (1) | CU20190067A7 (es) |
| EA (1) | EA201991600A1 (es) |
| EC (1) | ECSP19055179A (es) |
| IL (1) | IL268082A (es) |
| MX (1) | MX2019008993A (es) |
| NI (1) | NI201900075A (es) |
| PE (1) | PE20191479A1 (es) |
| PH (1) | PH12019550136A1 (es) |
| SG (1) | SG11201906959RA (es) |
| TW (1) | TWI674260B (es) |
| UA (1) | UA122746C2 (es) |
| UY (1) | UY37590A (es) |
| WO (1) | WO2018141855A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| ES2946632T7 (es) | 2018-02-06 | 2025-03-04 | Ideaya Biosciences Inc | Moduladores de AhR |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| US12473262B2 (en) | 2019-07-30 | 2025-11-18 | Oregon State University | Aryl hydrocarbon receptor activators |
| KR102351515B1 (ko) | 2019-12-17 | 2022-01-14 | (주)수파드엘릭사 | 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
| WO2021148628A1 (en) * | 2020-01-23 | 2021-07-29 | Phenex Pharmaceuticals Ag | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| US20240124444A1 (en) * | 2020-12-28 | 2024-04-18 | Celgene Corporation | Heterocyclic Compounds and Their Use for Parasitic Diseases |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
| EP4602034A2 (en) * | 2022-10-14 | 2025-08-20 | Oregon State University | Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992002500A1 (fr) | 1990-07-31 | 1992-02-20 | Teikoku Hormone Mfg. Co., Ltd. | Derive de 2-phenylindole |
| US6180643B1 (en) | 1996-11-19 | 2001-01-30 | Amgen Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| DE602006017741D1 (de) | 2005-11-18 | 2010-12-02 | Hoffmann La Roche | Azaindol-2-carboxamid-derivate |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| PT2488486T (pt) | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
| US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| US8604067B2 (en) * | 2009-11-02 | 2013-12-10 | Ahr Pharmaceuticals, Inc. | ITE for cancer intervention and eradication |
| HRP20140114T1 (hr) | 2010-02-03 | 2014-03-14 | Takeda Pharmaceutical Company Limited | Inhibitori kinaze 1 koji reguliraju signal apoptoze |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| CN107648216B (zh) | 2010-07-27 | 2021-03-30 | 波士顿大学管理委员会 | 作为新型癌症疗法的芳烃受体(AhR)调节剂 |
| GB201104267D0 (en) * | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| CA2888369A1 (en) | 2012-10-17 | 2014-04-24 | F. Hoffmann-La Roche Ag | 6-aminoindole derivatives as trp channel antagonists |
| EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) * | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-25 TW TW107102716A patent/TWI674260B/zh not_active IP Right Cessation
- 2018-01-31 AR ARP180100228A patent/AR110790A1/es unknown
- 2018-01-31 UY UY0001037590A patent/UY37590A/es unknown
- 2018-02-01 MX MX2019008993A patent/MX2019008993A/es unknown
- 2018-02-01 EP EP18707242.6A patent/EP3577115B1/en active Active
- 2018-02-01 US US16/479,847 patent/US11376241B2/en active Active
- 2018-02-01 WO PCT/EP2018/052538 patent/WO2018141855A1/en not_active Ceased
- 2018-02-01 PE PE2019001483A patent/PE20191479A1/es unknown
- 2018-02-01 CR CR20190393A patent/CR20190393A/es unknown
- 2018-02-01 EA EA201991600A patent/EA201991600A1/ru unknown
- 2018-02-01 CN CN201880009290.2A patent/CN110234650A/zh not_active Withdrawn
- 2018-02-01 CA CA3051034A patent/CA3051034A1/en not_active Withdrawn
- 2018-02-01 KR KR1020197025765A patent/KR20190113902A/ko not_active Ceased
- 2018-02-01 SG SG11201906959RA patent/SG11201906959RA/en unknown
- 2018-02-01 AU AU2018216955A patent/AU2018216955B2/en not_active Ceased
- 2018-02-01 CU CU2019000067A patent/CU20190067A7/es unknown
- 2018-02-01 BR BR112019015704A patent/BR112019015704A2/pt not_active Application Discontinuation
- 2018-02-01 UA UAA201908355A patent/UA122746C2/uk unknown
- 2018-02-01 JP JP2019561369A patent/JP2020505467A/ja not_active Ceased
-
2019
- 2019-07-15 IL IL268082A patent/IL268082A/en unknown
- 2019-07-15 NI NI201900075A patent/NI201900075A/es unknown
- 2019-07-23 CO CONC2019/0007882A patent/CO2019007882A2/es unknown
- 2019-07-24 PH PH12019550136A patent/PH12019550136A1/en unknown
- 2019-07-29 CL CL2019002112A patent/CL2019002112A1/es unknown
- 2019-07-31 EC ECSENADI201955179A patent/ECSP19055179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110234650A (zh) | 2019-09-13 |
| KR20190113902A (ko) | 2019-10-08 |
| ECSP19055179A (es) | 2019-08-30 |
| CA3051034A1 (en) | 2018-08-09 |
| PH12019550136A1 (en) | 2020-03-02 |
| NI201900075A (es) | 2019-10-30 |
| PE20191479A1 (es) | 2019-10-16 |
| JP2020505467A (ja) | 2020-02-20 |
| CO2019007882A2 (es) | 2019-10-09 |
| WO2018141855A1 (en) | 2018-08-09 |
| BR112019015704A2 (pt) | 2020-04-07 |
| IL268082A (en) | 2019-09-26 |
| US11376241B2 (en) | 2022-07-05 |
| SG11201906959RA (en) | 2019-08-27 |
| UY37590A (es) | 2018-02-28 |
| TW201838991A (zh) | 2018-11-01 |
| EA201991600A1 (ru) | 2020-03-10 |
| UA122746C2 (uk) | 2020-12-28 |
| EP3577115A1 (en) | 2019-12-11 |
| TWI674260B (zh) | 2019-10-11 |
| US20210260045A1 (en) | 2021-08-26 |
| EP3577115B1 (en) | 2020-12-02 |
| MX2019008993A (es) | 2019-12-19 |
| AR110790A1 (es) | 2019-05-02 |
| AU2018216955B2 (en) | 2020-09-17 |
| AU2018216955A1 (en) | 2019-08-01 |
| CL2019002112A1 (es) | 2019-12-20 |
| CU20190067A7 (es) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP19055169A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP19055179A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2020004519A (es) | Moduladores de la vía de estrés integrada. | |
| NI201800075A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos. | |
| UY36445A (es) | Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi) | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| UY35993A (es) | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina | |
| CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| MX2020006355A (es) | Pirrolidinamidas ii sustituidas. | |
| UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 |